Published in Parasitol Res on May 07, 2007
Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci U S A (2008) 1.96
Determinants for the development of visceral leishmaniasis disease. PLoS Pathog (2013) 1.22
Evaluation of antileishmanial potential of Tinospora sinensis against experimental visceral leishmaniasis. Parasitol Res (2007) 0.85
Antileishmanial activity in vitro and in vivo of constituents of sea cucumber Actinopyga lecanora. Parasitol Res (2008) 0.80
Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis. Parasitol Res (2013) 0.78
Clinical, hematological and biochemical alterations in hamster (Mesocricetus auratus) experimentally infected with Leishmania infantum through different routes of inoculation. Parasit Vectors (2016) 0.75
Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis. PLoS Negl Trop Dis (2016) 0.75
The aging immune system: primer and prospectus. Science (1996) 4.86
The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol (2001) 1.78
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg (1984) 1.62
Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. Infect Immun (2000) 1.22
The influence of age on immunity to infection with Mycobacterium tuberculosis. Immunol Rev (2005) 1.17
Effect of aging on murine macrophages. Diminished response to IFN-gamma for enhanced oxidative metabolism. J Immunol (1994) 1.09
Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg (2004) 1.06
Malnutrition, age and the risk of parasitic disease: visceral leishmaniasis revisited. Proc Biol Sci (1993) 0.97
Senescent BALB/c mice are able to develop resistance to Leishmania major infection. Infect Immun (2004) 0.96
Age-related decline in murine macrophage production of nitric oxide. J Infect Dis (1997) 0.90
Age-related susceptibility and resistance to Plasmodium berghei in mice and rats. Exp Parasitol (2003) 0.88
The effect of age and sex on incidence of kala-azar. J Commun Dis (1990) 0.87
Immunosuppression in hamsters with progressive visceral leishmaniasis: an evaluation of the role of nitric oxide toward impairment of the lymphoproliferative response. Parasitol Res (1999) 0.81
Sex-influenced population kinetics of Leishmania donovani in hamsters. Indian J Exp Biol (1990) 0.80
Some relationships between age, immune responsiveness and resistance to parasites in ruminants. Int J Parasitol (1997) 0.79
Effects of sex and age on the susceptibility of C57BL/6J mice to infection with Brachylaima cribbi and the course of infection in NOD SCID mice. Parasitol Res (2002) 0.78
Age-related increase in resistance to acute Trypanosoma cruzi infection in rats is associated with an appropriate antibody response. Scand J Immunol (2003) 0.77
Age-dependent resistance to Cryptosporidium muris (strain MCR) infection in golden hamsters and mice. Korean J Parasitol (1999) 0.76
Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP). Acta Trop (2009) 1.47
Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother (2008) 1.26
Animal models for vaccine studies for visceral leishmaniasis. Indian J Med Res (2006) 1.21
Squamous cell carcinoma of kidney co-existing with renal calculi: a rare tumour. BMJ Case Rep (2011) 1.15
Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: an approach for rational drug design. J Antimicrob Chemother (2008) 1.14
Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics (2007) 1.11
Short report: fluorescent Leishmania: application to anti-leishmanial drug testing. Am J Trop Med Hyg (2004) 1.08
Strategies for the production of recombinant protein in Escherichia coli. Protein J (2013) 1.02
Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis. J Immunol (2009) 1.02
Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol (2011) 0.98
Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. J Antimicrob Chemother (2009) 0.97
Pro-apoptotic effect of the landrace Bangla Mahoba of Piper betle on Leishmania donovani may be due to the high content of eugenol. J Med Microbiol (2009) 0.94
Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br J Clin Pharmacol (2010) 0.93
Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis. Eur J Immunol (2009) 0.90
Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis. J Antimicrob Chemother (2012) 0.88
Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis. Vaccine (2008) 0.88
Partial penile amputation due to penile tourniquet syndrome in a child troubled with primary nocturnal enuresis--a rare emergency. Urology (2013) 0.87
Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis. PLoS One (2012) 0.87
Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. Antimicrob Agents Chemother (2013) 0.87
Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis. PLoS One (2012) 0.86
Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Vaccine (2005) 0.86
Video Endoscopic Inguinal Lymphadenectomy (VEIL)--a prospective critical perioperative assessment of feasibility and morbidity with points of technique in penile carcinoma. World J Surg Oncol (2013) 0.85
Evaluation of antileishmanial potential of Tinospora sinensis against experimental visceral leishmaniasis. Parasitol Res (2007) 0.85
A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. Int J Parasitol (2012) 0.84
Unsuspected pheochromocytoma of the urinary bladder: reminder of an important clinical lesson. BMJ Case Rep (2012) 0.84
Over-expression of 60s ribosomal L23a is associated with cellular proliferation in SAG resistant clinical isolates of Leishmania donovani. PLoS Negl Trop Dis (2013) 0.84
Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target (2007) 0.84
Leishmania donovani pteridine reductase 1: biochemical properties and structure-modeling studies. Exp Parasitol (2008) 0.83
Laparoscopic cholecystectomy in situs inversus: points of technique. BMJ Case Rep (2012) 0.83
Peganine hydrochloride dihydrate an orally active antileishmanial agent. Bioorg Med Chem Lett (2009) 0.83
Cytodiagnosis of cutaneous metastases from gall bladder carcinoma on scalp. J Cytol (2012) 0.83
Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses. J Antimicrob Chemother (2011) 0.83
An orally effective dihydropyrimidone (DHPM) analogue induces apoptosis-like cell death in clinical isolates of Leishmania donovani overexpressing pteridine reductase 1. Parasitol Res (2009) 0.82
Trans-anal barotrauma by compressed air leading to sigmoid perforation due to a dangerous practical joke. BMJ Case Rep (2012) 0.82
Novel features of a PIWI-like protein homolog in the parasitic protozoan Leishmania. PLoS One (2012) 0.82
Amplified fragment length polymorphism (AFLP) analysis is useful for distinguishing Leishmania species of visceral and cutaneous forms. Acta Trop (2009) 0.82
In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J Drug Target (2010) 0.81
Intake of nutrient supplements affects multiplication of Leishmania donovani in hamsters. Parasitology (2004) 0.81
Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation. Mol Pharm (2014) 0.81
Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis. Vaccine (2005) 0.80
Glycolipids and other constituents from Desmodium gangeticum with antileishmanial and immunomodulatory activities. Bioorg Med Chem Lett (2005) 0.80
Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis. J Liposome Res (2011) 0.80
Antileishmanial activity in vitro and in vivo of constituents of sea cucumber Actinopyga lecanora. Parasitol Res (2008) 0.80
Tetracycline treatment targeting Wolbachia affects expression of an array of proteins in Brugia malayi parasite. Proteomics (2009) 0.79
Obesity: single house for many evils. Minerva Endocrinol (2016) 0.78
Uptake of biodegradable gel-assisted LBL nanomatrix by Leishmania donovani-infected macrophages. AAPS PharmSciTech (2009) 0.78
Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis. Parasitol Res (2013) 0.78
Leishmania donovani: oral therapy with glycosyl 1,4-dihydropyridine analogue showing apoptosis like phenotypes targeting pteridine reductase 1 in intracellular amastigotes. Exp Parasitol (2010) 0.78
Development of doxorubicin loaded novel core shell structured nanocapsules for the intervention of visceral leishmaniasis. J Microencapsul (2013) 0.78
Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies. Pharm Res (2015) 0.78
Unresponsiveness of Mycobacterium w vaccine in managing acute and chronic Leishmania donovani infections in mouse and hamster. Parasitology (2012) 0.78
Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. J Microencapsul (2011) 0.77
Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles. Appl Biochem Biotechnol (2014) 0.77
Efficacy of human beta-casein fragment (54-59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters. Peptides (2004) 0.77
Mass spectrometry-based proteomic analysis of Leishmania donovani soluble proteins in Indian clinical isolate. Pathog Dis (2014) 0.77
16alpha-Hydroxycleroda-3,13 (14)Z-dien-15,16-olide from Polyalthia longifolia: a safe and orally active antileishmanial agent. Br J Pharmacol (2010) 0.77
Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis. Proteomics Clin Appl (2008) 0.77
Destruction of hydrogen bonds of poly(N-isopropylacrylamide) aqueous solution by trimethylamine N-oxide. J Chem Phys (2012) 0.77
Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos. Expert Opin Drug Deliv (2013) 0.76
Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. Curr Drug Targets (2008) 0.76
Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis. Bioconjug Chem (2014) 0.76
Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies. Nanomedicine (Lond) (2015) 0.76
Identification of novel S-adenosyl-L-homocysteine hydrolase inhibitors through homology-model-based virtual screening, synthesis, and biological evaluation. J Chem Inf Model (2012) 0.76
Tocopherol from seeds of Cucurbita pepo against diabetes: validation by in vivo experiments supported by computational docking. J Formos Med Assoc (2013) 0.76
The solubility and stability of amino acids in biocompatible ionic liquids. Protein Pept Lett (2014) 0.75
Efficacy of Desmodium gangeticum extract and its fractions against experimental visceral leishmaniasis. J Ethnopharmacol (2005) 0.75
Emerging role of vesicular carriers for therapy of visceral leishmaniasis: conventional versus novel. Crit Rev Ther Drug Carrier Syst (2010) 0.75
Correction: Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis. PLoS Negl Trop Dis (2015) 0.75
Primary amyloidoma of chest wall--a rare condition. BMJ Case Rep (2012) 0.75
Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters. PLoS One (2012) 0.75
Incidentally diagnosed right-sided intrathoracic kidney. BMJ Case Rep (2012) 0.75
Constituents of Tinospora sinensis and their antileishmanial activity against Leishmania donovani. Nat Prod Res (2009) 0.75
Anticoagulant-induced priapism progressing to penile gangrene: a devastating complication! BMJ Case Rep (2012) 0.75
Development and characterization of doxorubicin loaded microparticles against experimental visceral leishmaniasis. J Biomed Nanotechnol (2011) 0.75
Presbytis entellus: a primate model for parasitic disease research. Trends Parasitol (2004) 0.75
A Prospective Randomized Controlled Trial Comparing Quality of Life Following Endoscopic Totally Extraperitoneal (TEP) Versus Open Stoppa Inguinal Hernioplasty. Surg Laparosc Endosc Percutan Tech (2017) 0.75
Design and development of Amphotericin B bearing polycaprolactone microparticles for macrophage targeting. J Biomed Nanotechnol (2011) 0.75
Investigations on feasibility of in situ development of amphotericin B liposomes for industrial applications. J Liposome Res (2011) 0.75
Amplified fragment length polymorphism: an adept technique for genome mapping, genetic differentiation, and intraspecific variation in protozoan parasites. Parasitol Res (2012) 0.75